| Drug Type AAV based gene therapy | 
| Synonyms BB-202, BB-AMD-211, TT-211 + [1] | 
| Target | 
| Action inhibitors | 
| Mechanism PIGF inhibitors(phosphatidylinositol glycan anchor biosynthesis class F inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), VEGF-B inhibitors(Vascular endothelial growth factor B inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Wet Macular Degeneration | Preclinical | - | - | 





